Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Search content at Albert Einstein College of Medicine
Home
Faculty
Departments
Grants
Publications
Prizes
WCA Recommendations for the Long-Term Treatment of Social Phobia
Michael Van Ameringen
, Christer Allgulander
, Borwin Bandelow
, John H. Greist
,
Eric Hollander
, Stuart A. Montgomery
, David J. Nutt
, Ahmed Okasha
, Mark H. Pollack
, Dan J. Stein
, Richard P. Swinson
Research output
:
Contribution to journal
›
Article
›
peer-review
42
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'WCA Recommendations for the Long-Term Treatment of Social Phobia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Long-term Treatment
100%
Social Anxiety Disorder
100%
Anxiety Disorders
20%
Selective Serotonin Reuptake Inhibitors
20%
Clonazepam
20%
Clinical Course
10%
Comorbidity
10%
Tolerability
10%
Treatment Strategy
10%
Effective Treatment
10%
Monoamine Oxidase Inhibitors
10%
Benzodiazepines
10%
Disability
10%
Complete Remission
10%
Cognitive Behavioral Therapy
10%
Prevalence Rate
10%
Drug Efficacy
10%
Randomized Clinical Trial
10%
Treatment Effect
10%
Treatment Trials
10%
Social Interaction
10%
Functional Impairment
10%
Relapse Rate
10%
Short-term Treatment
10%
Mood Disorders
10%
Social Performance
10%
Professional Help
10%
Non-reversible
10%
Treatment Lines
10%
Other Psychiatric Disorders
10%
Treatment Data
10%
Being Seen
10%
Substance Abuse/dependence
10%
Pharmacology, Toxicology and Pharmaceutical Science
Social Phobia
100%
Selective Serotonin Reuptake Inhibitor
20%
Anxiety Disorder
20%
Clonazepam
20%
Disease Course
10%
Prevalence
10%
Recurrence Risk
10%
Clinical Study
10%
Benzodiazepine
10%
Remission
10%
Randomized Clinical Trial
10%
Tolerability
10%
Functional Disease
10%
Mood Disorder
10%
Monoamine Oxidase Inhibitor
10%
Chronicity
10%
Comorbidity
10%
Disability
10%
Psychology
Social Anxiety
100%
Anxiety Disorder
22%
Clonazepam
22%
Comorbidity
11%
Benzodiazepine
11%
Social Anxiety Disorder
11%
Functional Impairment
11%
Cognitive Behavioral Therapy
11%
Adolescence
11%
Mood Disorder
11%
Clinical Trial
11%
Neuroscience
Social Anxiety Disorder
100%
Selective Serotonin Reuptake Inhibitor
20%
Anxiety Disorder
20%
Clonazepam
20%
Mental Disorder
10%
Monoamine Oxidase Inhibitor
10%
Mood Disorder
10%
Benzodiazepine
10%
Cognitive Behavioral Therapy
10%
Comorbidity
10%